|4Jun 26, 4:54 PM ET

Chiesi Ventures, Inc. 4

4 · Kezar Life Sciences, Inc. · Filed Jun 26, 2018

Insider Transaction Report

Form 4
Period: 2018-06-25
Transactions
  • Conversion

    Common Stock, par value $0.001 per share

    2018-06-25+314,819314,819 total(indirect: See footnote)
  • Conversion

    Series B Preferred Stock, par value $0.001 per share

    2018-06-25+314,8190 total(indirect: See footnote)
    Common Stock (314,819 underlying)
Footnotes (2)
  • [F1]The Series B Preferred Stock, par value $0.001 per share, converted into Common Stock, par value $0.001 per share, on a one-for-one basis and had no expiration date.
  • [F2]These shares are held of record by Chiesi Ventures, LP ("Chiesi Ventures"). Chiesi Ventures, Inc. ("Chiesi") is the general partner of Chiesi Ventures, and Mr. Giacomo Chiesi is President of, and may be deemed to have control of, Chiesi. By virtue of their respectively relationships with Chiesi Ventures, each of Chiesi and Mr. Chiesi may be deemed to indirectly beneficially own the shares of which Chiesi Ventures is the record owner. Each of Chiesi and Mr. Chiesi disclaims beneficial ownership of the shares reported herein, except to the extent of its or his respective pecuniary interests therein. This report shall not be deemed an admission that such reporting persons are the beneficial owners of such securities for purposes of Section 16 or for any other purpose.

Documents

1 file
  • 4
    tv497342_form4.xmlPrimary

    FORM 4